Taysha Gene Therapies (TSHA) Tops Q1 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.41 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies (TSHA) PT Raised to $14 at BMO Capital on Differentiation
• FedEx (FDX) PT Lowered to $397 at Bernstein SocGen Group
• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’